1. Choroideremia, Sensorineural Deafness, And Primary Ovarian Failure In A Woman Wi leading to a contiguous gene deletion syndrome. The primary ovarian failure (POF) found in the present case has been http://www.szp.swets.nl/szp/journals/og213185.htm

Ophthalmic Genetics 2000, Vol.21, No.3, pp. 185-189 Case report Choroideremia, sensorineural deafness, and primary ovarian failure in a woman with a balanced X-4 translocation Isabel Lorda-Sanchez , Angeles Ibañez , Raúl Sanz , María J. Trujillo , Marian Anabitarte , María E. Querejeta , Marta Rodriguez de Alba , Ascension Gimenez , Fernando Infantes , Carmen Ramos , Blanca Garcia-Sandoval and Carmen Ayuso Fundacion Jimenez Diaz, Department of Genetics, Madrid, Spain Universidad Complutense, Department of Cellular Biology, Madrid, Spain Policlínica de Guipuzcoa, Unit of Genetics, San Sebastian, Spain Fundacion Jimenez Diaz, Department of Ophthalmology, Madrid, Spain Keywords: Choroideremia , chromosome X , POF , translocation , chromosome 4 .

2. POF Support Group: Premature Ovarian Failure Program Nr 856 primary ovarian failure associated to a 46 XX t(6;18)(p23;q22) balanced reciprocal translocation. Possible new autosomal genes involved in ovarian development. Llerena Jr.1 2, J.C. Cabral de Almeida1 2. http://www.pofsupport.org/

Your browser does not support script Home What's New FAQ's Contact Us For most women, the diagnosis of Premature Ovarian Failure (POF) is a devastating one. At a time when we should be feeling our healthiest, we must cope with a chronic disorder and infertility. Often, before we've even had the chance to make a decision about having children, the opportunity is denied. The goals of this group are to offer support and information to women who have been diagnosed with Premature Ovarian Failure. This website contains a wealth of information and support, designed to help you learn about POF, stay up to date with the latest research, meet other women with POF, take control of your health care, and guide you through the various aspects of living with premature ovarian failure. We hope you find what you're looking for on our website and take the opportunity to participate in interactive areas of our site - message boards, email lists, chats and meet some incredibly knowledgeable and supportive women along your journey!

3. Overcoming Infertility primary ovarian failure. Failure of the ovaries to produce enough follicles,because of a problem in the ovary itself, and resulting http://www.jansen.com.au/glossary.asp?keyword=primary ovarian failure

4. Overcoming Infertility or timewise (eg a primary follicle gives rise to a secondary follicle, then toa tertiary follicle); or (3) causally (eg primary ovarian failure is based http://www.jansen.com.au/glossary.asp?keyword=primary

5. EMedicine - Ovarian Failure : Article Excerpt By: Vladimir Bakalov, MD Related Terms premature ovarian failure, primary ovarian failure, premature menopause, primary ovarian insufficiency, http://www.emedicine.com/med/byname/ovarian-failure.htm

(advertisement) Excerpt from Ovarian Failure Synonyms, Key Words, and Related Terms: premature ovarian failure, primary ovarian failure, premature menopause, primary ovarian insufficiency, POF Please click here to view the full topic text: Ovarian Failure Background: The human ovary functions as both a reproductive organ and an endocrine organ. These functions are tightly coupled. Predictable cyclicity is the hallmark of healthy ovarian function during the reproductive years. Each month, highly coordinated hormonal and ovarian morphological changes develop and release a mature oocyte that is ready for fertilization. A disruption of this process results in reproductive failure (anovulation) or endocrine failure (low serum levels of ovarian steroid hormones and inhibins). Ovarian failure due to inappropriate regulatory signals (hypothalamic or pituitary pathology) is known as secondary ovarian failure. Ovarian failure due to a pathological process directly affecting the ovaries (eg, chemotherapy, irradiation, autoimmunity, chromosomal abnormalities) is known as primary ovarian failure (POF). A simple means of distinguishing between the 2 conditions is to measure serum follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels (elevated in POF and low or normal in secondary ovarian failure). Aging is associated with a decline in the number of ovarian follicles, menstrual irregularities, ovarian hormonal deficiency, anovulation, decreased fertility, and, finally, a complete and irreversible cessation of menses known as menopause, usually occurring at a mean age of 51 years.

6. Vivelle-Dot® - Estrogen Replacement Therapy Through Estrogen Patches For Oophor vasomotor symptoms associated with menopause; vulvar and vaginal atrophy; hypoestrogenismdue to hypogonadism, castration, or primary ovarian failure; and the http://vivelle.accrisoft.com/professionals_comparepatch.php

Home Healthcare Professionals Patch Comparison Here are some photos of ERT patches. Take a look and see for yourself that Vivelle-Dot is the smallest ERT patch available. **Vivelle-Dot, the revised formulation with smaller system sizes, was shown to be bioequivalent to the original formulation, Vivelle, used in the the clinical trials. Send this page to a colleague Vivelle-Dot PI Estraderm PI The information contained within this web site is appropriate for U.S. Healthcare Professionals only. Rx only. Sustained Delivery of plant-derived estradiol. Vivelle-Dot (estradiol transdermal system) is indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause; vulvar and vaginal atrophy; and the prevention of postmenopausal osteoporosis. Vivelle-Dot 0.025 mg/day is indicated for the prevention of postmenopausal osteoporosis only. In clinical trials, systemic adverse events with Vivelle

7. LH: The Test In women, LH and FSH levels can help to differentiate between primary ovarian failure(failure of the ovaries themselves or lack of ovarian development) and http://www.labtestsonline.org/understanding/analytes/lh/test.html

TESTS test not listed? ACTH AFB Culture AFP Maternal AFP Tumor Marker Albumin Aldosterone Allergies ALP ALT Amylase ANA Antibody Tests Apo A Apo B ApoE Genotyping AST Bilirubin Blood Culture Blood Gases BMP BNP Bone Markers BRCA BUN C-peptide CA-125 CA 15-3 CA 19-9 Calcium Cardiac Risk CBC CEA CF Gene Mutation Chlamydia Chloride Cholesterol CK CK-MB CMP Cortisol Creatinine Creatinine Clearance CRP CRP, high-sensitivity Cystatin C DHEAS Differential EGFR Electrolytes ESR Estrogen Estrogen Receptors Fecal Occult Blood Ferritin Flu Tests FSH Genotypic Resistance GFR GGT Glucose Gonorrhea Gram Stain Growth Hormone hCG HDL Hematocrit Hemoglobin Hepatitis A Hepatitis B Hepatitis C Her-2/neu Herpes HIV Antibody Home Tests Homocysteine HPV H-pylori hs-CRP Insulin Iron Tests LD LDH LDL Lead LH Lipase Lipid Profile Liver Panel Lp(a) Lyme Disease Magnesium Microalbumin Mono Monoclonal Protein Myoglobin Pap Smear Phosphorus Platelets Potassium Prealbumin Progesterone Progest. Receptors Prolactin PSA PT PTH Red Count Renin Rheumatoid Factor Rubella Semen Analysis Serum Iron Sickle Cell Sodium Strep Throat Sweat Chloride Syphilis Tau/Aß42 TB Skin Test Testosterone Ther. Drug Monitoring

8. Ferring.com FerCenter Infertility Resource - The Genetics Of Human Ovarian Failu Hector Nemirovsky, MD You dont foresee any solution of this type of thing, the primary ovarian failure? http://www.fercenter.com/display.asp?page=interviews_congress-reporting_WC2002_m

9. Bone Loss In Post Chemotherapy Ca Breast Patients With Ovarian Failure This site provides support and information for women with Premature Ovarian Failure (POF). Endocrine disorder affecting women under 40, causes profound infertility and vasomotor symptoms. Often called Premature or Early Menopause. Includes a POF FAQ the incidence for Premature Ovarian Failure. She did the http://www.indegene.com/Onc/Jour/indJour_JCON_Sum_01-07-2001_2.asp

Select a Speciality Cardiology Endocrinology ENT Family Medicine Gastroenterology Gynaecology Internal Medicine Nephrology Neurology Oncology Ophthalmology Orthopaedics Paediatrics Psychiatry Pulmonology Radiology Ask Indegene Discussions Notice Board Journal Scan ... Medico-Legal Cases Bone Loss In Post Chemotherapy Ca Breast Patients With Ovarian Failure Primary ovarian failure occurs in 50-85 percent of invasive breast cancer patients undergoing adjuvant chemotherapy. Consequent to an increasing population of mammographically detected early cases in younger age group, enlarging proportion of long-term breast cancer survivors and NIH recommendation of adjuvant chemotherapy to invasive cancers as low as 1 cm of size, has resulted in a large population susceptible for such estrogen withdrawal side effects. One such side effect could be osteopenia with subsequent osteoporosis. Forty-nine premenopausal women with stage I/II receiving adjuvant chemotherapy was evaluated for ovarian failure and bone loss, in the present study. Among 35 patients who were defined as having ovarian failure, highly significant decrease in bone mineral density (BMD) was observed in lumbar spine and femur by 6 months (-4.0, range –10.4 to +1.0, p=0.001) and increased further at 12 months (-3.7, range –10.1 to 9.2; p=0.001). In contrast, there was no significant decrease in bone mineral density in the 14 patients who retained ovarian function. Serum osteocalcin, bone specific alkaline phosphatase and markers of skeletal turnover also significantly increased in women who developed ovarian failure. The chemotherapy induced decreased BMD is presumably due to rapid decrease in estrogen levels, unlike in natural menopause where the estrogen levels wax and wane and decline over several years.

10. Menotropins Uses Females In combination with HCG to induce ovulation in clientswith anovulatory cycles not due to primary ovarian failure. http://www.nursespdr.com/members/database/ndrhtml/menotropins.html

Menotropins Menotropins (Pergonal) Menotropins (men-oh- TROH -pinz) Pregnancy Category: X Humegon Pergonal Repronex (Rx) Classification: Ovarian stimulant Action/Kinetics: Menotropins are a mixture of FSH and LH extracted from the urine of postmenopausal women. Causes growth and maturation of ovarian follicles. For ovulation to occur, HCG is administered the day following menotropins. Time to peak effect, females: 18 hr. In men, menotropins with HCG given for a minimum of 3 months induce spermatogenesis. Eliminated through the kidneys. Uses: Females: In combination with HCG to induce ovulation in clients with anovulatory cycles not due to primary ovarian failure. Use Repronex in conjunction with HCG for multiple follicular development and induction of ovulation in clients who have previously received pituitary suppression. Males: In combination with HCG to induce spermatogenesis in clients with primary or secondary hypogonadotrophic hypogonadism. Contraindications: Women: Pregnancy. Primary ovarian failure as indicated by high levels of urinary gonadotropins, ovarian cysts, intracranial lesions, including pituitary tumors. Overt thyroid and adrenal dysfunction. Any cause of infertility other than anovulation. Abnormal bleeding of undetermined origin. Ovarian cysts or enlargement of the ovaries not due to polycystic ovarian syndrome. Men: Normal gonadotropin levels, primary testicular failure, disorders of fertility other than hypogonadotrophic hypogonadism. Thyroid or adrenal dysfunction. Absence of neoplastic disease should be established before treatment is initiated.

11. Urofollitropin For Injection women. Is a gonadotropin that stimulates follicular growth in the ovariesof women without primary ovarian failure. Because treatment http://www.nursespdr.com/members/database/archives/urofollitropinforinjection.ht

Urofollitropin for injection Urofollitropin for injection (Metrodin) Urofollitropin YOUR -oh-foll-ee- troh -pin) Pregnancy Category: X Metrodin (Rx) Urofollitropin for injection, purified (Ferntinex) Urofollitropin YOUR -oh-foll-ee- troh -pin) Pregnancy Category: X Fertinex Fertinorm HP (Rx) Classification: Ovarian stimulant Action/Kinetics: Prepared from the urine of postmenopausal women. Is a gonadotropin that stimulates follicular growth in the ovaries of women without primary ovarian failure. Because treatment with urofollitropin only causes growth and maturation of a follicle, HCG must also be given to effect ovulation. Time to peak effect: 32-36 hr after HCG. Uses: To cause ovulation in women with polycystic ovarian disease; such clients should have an elevated LH/FSH ratio and should have failed to respond to therapy with clomiphene. In conjunction with HCG to stimulate development and maturation of ovarian follicles and subsequent ovulation in clients with polycystic ovary syndrome and infertility. Use of the purified urofollitropin is said to cause less discomfort than use of the less purified urofollitropin product. Contraindications: Primary ovarian failure (as indicated by high levels of both LH and FSH), adrenal dysfunction, thyroid dysfunction, pituitary tumor, abnormal uterine bleeding of unknown cause, ovarian cysts, enlarged ovaries (not as a result of polycystic disease), infertility due to causes other than failure to ovulate. Pregnancy.

12. Newly Approved Drug Therapies (647): Ovidrel (gonadotropin, Chorionic Human Reco of ovulation (OI) and pregnancy in anovulatory infertile patients in whom thecause of infertility is functional and not due to primary ovarian failure. http://www.centerwatch.com/patient/drugs/dru647.html

Drugs Approved by the FDA Drug Name: Ovidrel (gonadotropin, chorionic human recombinant) The following information is obtained from various newswires, published medical journal articles, and medical conference presentations. Company: Serono Laboratories Approval Status: Approved September 2000 Treatment for: Infertility General Information Ovidrel has been approved for the induction of final follicular maturation and early luteinization in infertile women who have undergone pituitary desensitization and who have been appropriately pretreated with follicle stimulating hormones as part of an Assisted Reproductive Technology (ART) program. Also indicated for the induction of ovulation (OI) and pregnancy in anovulatory infertile patients in whom the cause of infertility is functional and not due to primary ovarian failure. (From FDA Label) It is available by prescription only and is in an injectable formulation. Clinical Results Two assisted reproductive technologies (ART) studies were held to evaluate the safety and efficacy of Ovidrel at two dosage levels, 250mcg and 500mcg. The drug was administered subcutaneously in a randomized, open-label, 20 center study to infertile women undergoing in vitro fertilization and embryo transfer in the U.S.. 297 patients entered the study, 94 were randomized to receive Ovidrel 250mcg. The primary efficacy parameter was the number of oocytes retrieved. This number was similar for the Ovidrel and urinary-derived hCG treatment groups. Efficacy for Ovidrel 250mcg and Ovidrel 500mcg were both found to be clinically and statistically equivalent to each other and to the urinary-derived hCG treatment group.

13. About HRT Most women with primary ovarian failure opt for long term oestrogen replacement therapyin order to prevent symptoms of oestrogen deficiency and osteoporosis. http://www.daisynetwork.org.uk/abouthrt.htm

About HRT Premature ovarian failure - treatment The diagnosis of premature ovarian failure in a young women is a devastating event. One of the most neglected aspects of POF is the long-term psychological scarring left by the diagnosis. This is especially true of younger women who experience low self-esteem and depression which cannot be accounted for solely by oestrogen deficiency. Counselling or patients support group should be offered to all women. Hormone replacement therapy Most women with primary ovarian failure opt for long term oestrogen replacement therapy in order to prevent symptoms of oestrogen deficiency and osteoporosis. The youngest women may require HRT for nearly 40 years. The degree to which this long term administration of oestrogen prevents cardiovascular disease or increases risk of breast cancer is unknown and we can only extrapolate from studies in older postmenopausal women. Progesterone is required for all women with an intact uterus in order to avoid endometrial hyperplasia induced by unopposed oestrogen. While some women might find the continuous combined form of oestrogen and progesterone replacement attractive as a way of avoiding menstruation, it must be remembered that the use of these preparations in young women has not been studied over the long-term. Testosterone supplements are rarely required when the adrenal gland continues to supply androgens. Even though testosterone implants have a reputation for improving libido, they have not being tested in a controlled clinical trial. For those women with combined ovarian failure and Addison's disease who have no source of androgens, it seems reasonable to offer testosterone replacement.

14. Introduction Women who have a defective LH recepto r present with primary amenorrhoeawith the typical picture of primary ovarian failure. In http://www.daisynetwork.org.uk/pofintro.htm

Premature Ovarian Failure A brief background to the causes of premature ovarian failure by Dr Gerard Conway - Consultant Endocrinologist, The Middlesex Hospital, Mortimer Street, London W1N 8AA Introduction In the United Kingdom the age distribution of the menopause has a median at the age of 50 years with one percent of women menstruating after the age of 60 and one percent entering menopause before the age of 40. The age of the natural menopause is closely inherited and it is also affected by environmental factors such as smoking. A menopause before the age of 40 is most commonly taken to be the definition of 'premature ovarian failure' although this figure is arbitrary. Estimates of the prevalence of premature ovarian failure range between 0.3 and 1% and this condition account for approximately 25% of women presenting amenorrhoea. The ovary comprises four cell types, germ cells, granulosa cells, theca cells and support cells. The integrity of germ cells and granulosa cells is closely interdependent so their survival and failure occur in parallel. Some mechanisms of ovarian failure primarily result in germ cell depletion, X chromosome abnormalities for instance, while others target granulosa cells only, e.g. FSH receptor mutations. Terminology Here are some terms which are applied to differences in timing and severity of ovarian failure: Gonadal dysgenesis describes the failure of the ovary to develop but is also loosely applied to the presentation of ovarian failure with primary amenorrhoea and failure to develop secondary sexual characteristics.

15. 856 Primary Ovarian Failure Associated To A 46,XX,t(6;18)(p23; primary ovarian failure associated to a 46,XX,t(6;18)(p23;q22) balanced reciprocaltranslocation. primary ovarian failure has heterogeneous causes. http://www.faseb.org/genetics/ashg99/f856.htm

16. Apthorp Infertility Pharmacy:- Products and pregnancy in the anovulatory infertile patient in whom the cause of infertilityis functional and not due to primary ovarian failure (inability of the http://www.apthorp.com/products.cfm

We're the Infertility Pharmacy Fertility Medications Women have two ovaries located in the pelvis alongside the uterus. Their main functions are to release eggs and produce hormones. At birth, the ovaries contain thousands of eggs, each surrounded by cells that develop into small fluid-filled blisters known as follicles. When a woman is ovulating normally, each month one of these follicles will grow to about 20 millimeters in diameter and release an egg (ovulation). The egg then passes down the fallopian tubes, where fertilization occurs. The fertilized egg (embryo) travels to the uterus to implant itself in the lining (endometrium) and develop as a pregnancy. If the egg is not fertilized in the fallopian tubes, the endometrium is shed as a menstrual period about 14 days after ovulation. The normal female reproductive cycle is principally controlled by hormones released from several organs in the body. At the base of the brain, the hypothalamus gland produces gonadotropin-releasing hormone (GnRH) . This hormone, in turn, stimulates the pituitary gland to release two important reproductive hormones:

17. Research Festival 2002 ongoing controversy regarding the best method to diagnose autoimmune premature ovarianfailure (POF), a potentially treatable form of primary ovarian failure. http://festival02.nih.gov/search.taf?_function=detail&&t_Posters_uid1=154

18. Ovulation Disorders As A Cause Of Infertility Only primary ovarian failure, and the related conditions of resistant ovary syndromeand autoimmune oophoritis, are considered untreatable in regards to http://infertility.about.com/library/ifctr/blovdis.htm

zfp=-1 About Infertility Search in this topic on About on the Web in Products Web Hosting Infertility with Apply Now Your Guide to one of hundreds of sites Home Articles Forums ... Help zmhp('style="color:#fff"') Subjects ESSENTIALS Answers to Frequently Asked Questions How Tos Center for Resolutions to Infertility ... All articles on this topic Stay up-to-date! Subscribe to our newsletter. Advertising Free Credit Report Free Psychics Advertisement Ovulation Disorders Ovulation disorders, infrequent or absent ovulation (anovulation), typically result in infrequent periods (oligomenorrhea). The results are fewer opportunities to conceive difficulty detecting a woman's fertile periods eggs not breaking through the follicle eggs being released off-sync with other factors crucial to fertilization or implantation More typical causes of ovulation disorders include: hypothalamus dysfunction hyperprolactinemia polycystic ovarian syndrome luteal phase defect tumors of the pituitary or adrenal glands or ovaries Less typical causes of ovulation disorder are: primary ovarian failure Resistant ovary syndrome Autoimmune oophoritis Diagnosis In general, assessment for ovulation disorders may begin with the following lab tests:

19. Human FSH (hFSH) - Infertility Treatment Drugs Serono). Form Subcutaneous injection. Indications Demonstrated ovulatory dysfunctionwith No current pregnancy; No evidence of primary ovarian failure; http://infertility.about.com/library/ifctr/blhfsh.htm

zfp=-1 About Infertility Search in this topic on About on the Web in Products Web Hosting Infertility with Apply Now Your Guide to one of hundreds of sites Home Articles Forums ... Help zmhp('style="color:#fff"') Subjects ESSENTIALS Answers to Frequently Asked Questions How Tos Center for Resolutions to Infertility ... All articles on this topic Stay up-to-date! Subscribe to our newsletter. Advertising Free Credit Report Free Psychics Advertisement Human FSH (hFSH) Classification: human urofollitropins Brand Names: Fertinex®, Metrodin HP® (mfg. Serono) Form: Subcutaneous injection Indications: Demonstrated ovulatory dysfunction with: No current pregnancy No evidence of primary ovarian failure No uncontrolled thyroid or adrenal dysfunction No ovarian cysts (except in case of PCOS) Used in conjunction with hCG Used for: In women, inducing ovarian follicular growth and maturation. May be particularly useful for women with PCOS ( polycystic ovarian syndrome How does it work? Possesses hormonal activities of follicle stimulating hormone (FSH). Suggested Evaluations: Pre-RX: thyroid disease ovarian enlargement or cyst formation uterine fibroid tumors undiagnosed unusual vaginal bleeding estrogen levels primary pituitary or ovarian failure or enlargement evidence of prostate cancer in men testicular failure renal and hepatic functions During RX: mid-cycle urine LH test (OPK) estrogen levels progesterone levels mid-cycle ultrasound to detect follicle development Usual Dosage: Dosage must be carefully determined for each patient, and may be changed during treatment cycle.

20. Gynogen of ovulation and pregnancy in the anovulatory infertile patient, in whom the causeof anovulation is functional and is not due to primary ovarian failure. http://www.pubergen.com/gynogen.htm

Solutions for future power GYNOGEN COMPOSITION MENOTROPHIN (Human Menopausal Gonadotrophin ,H.M.G) FOR INTRAMUSCULAR USE ONLY. Each ampoule of GYNOGEN 75 I.U. of Follicle-stimulating hormone (FSH) activity and 75 I.U. of Luteinising hormone (LH) activity. Each ampoule of GYNOGEN 150 I.U. of Follicle-stimulating hormone (FSH) activity and 150 I.U. of Luteinising hormone (LH) activity. INDICATIONS AND USAGE FEMALES GYNOGEN and PUBERGEN given in a sequential manner are indicated for the induction of ovulation and pregnancy in the anovulatory infertile patient, in whom the cause of anovulation is functional and is not due to primary ovarian failure. MALES GYNOGEN With concomitant PUBERGEN is indicated for the stimulation of spermatogenesis in men who have primary or secondary hypogonadotrophic hypogonadism. GYNOGEN With concomitant PUBERGEN has proven effective in inducing spermatogenesis in men with primary hypogonadism due to a congenital factor or prepubertal hypophysectomy and in men with secondary hypogonadotrophic hypogonadism due to hypophysectomy, craniopharyngioma, cerebral aneurysm or chromophobe adenoma.

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Page 1     1-20 of 85    1  | 2  | 3  | 4  | 5  | Next 20